CRISM Therapeutics Corporation (CRTX) — Working Capital to Net Assets Ratio
CRISM Therapeutics Corporation (CRTX) has a Working Capital to Net Assets ratio of 90.1% as of December 2025. Working capital of GBX1.28 Million (current assets of GBX1.66 Million minus current liabilities of GBX381.00K) is measured against net assets of GBX1.42 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See CRISM Therapeutics Corporation liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
CRISM Therapeutics Corporation Working Capital to Net Assets (2006–2025)
This chart shows how CRISM Therapeutics Corporation's Working Capital to Net Assets ratio has evolved across 20 annual periods from 2006 to 2025. As of December 2025, the ratio stands at 90.1%, reflecting working capital of GBX1.28 Million against net assets of GBX1.42 Million GBX. For the complete balance sheet picture, see CRISM Therapeutics Corporation (CRTX) total assets.
Annual Working Capital to Net Assets for CRISM Therapeutics Corporation (2006–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for CRISM Therapeutics Corporation from 2006 to 2025, covering 20 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check CRTX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (GBX) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 90.1% | GBX1.28 Million | GBX1.42 Million | GBX1.66 Million | GBX381.00K | ▼ -1.3 pp |
| 2024 | 91.5% | GBX1.35 Million | GBX1.48 Million | GBX1.69 Million | GBX341.00K | ▲ +22.6 pp |
| 2023 | 68.8% | GBX-522.94K | GBX-759.66K | GBX13.00K | GBX535.94K | ▲ +58.8 pp |
| 2022 | 10.1% | GBX2.33 Million | GBX23.13 Million | GBX2.95 Million | GBX619.34K | ▼ -3.4 pp |
| 2021 | 13.4% | GBX4.05 Million | GBX30.11 Million | GBX5.01 Million | GBX964.05K | ▲ +6.3 pp |
| 2020 | 7.2% | GBX2.24 Million | GBX31.35 Million | GBX3.15 Million | GBX913.00K | ▲ +7.4 pp |
| 2019 | -0.3% | GBX-60.39K | GBX20.48 Million | GBX668.05K | GBX728.44K | ▲ +3.6 pp |
| 2018 | -3.9% | GBX-913.00K | GBX23.48 Million | GBX1.71 Million | GBX2.62 Million | ▼ -15.6 pp |
| 2017 | 11.7% | GBX3.30 Million | GBX28.20 Million | GBX4.07 Million | GBX768.00K | ▼ -11.8 pp |
| 2016 | 23.5% | GBX6.01 Million | GBX25.55 Million | GBX9.72 Million | GBX3.71 Million | ▼ -23.0 pp |
| 2015 | 46.5% | GBX7.07 Million | GBX15.21 Million | GBX7.68 Million | GBX615.14K | ▲ +3.9 pp |
| 2014 | 42.6% | GBX8.83 Million | GBX20.72 Million | GBX9.09 Million | GBX261.02K | ▲ +6.0 pp |
| 2013 | 36.6% | GBX6.61 Million | GBX18.05 Million | GBX6.68 Million | GBX74.25K | ▲ +5.1 pp |
| 2012 | 31.6% | GBX5.09 Million | GBX16.12 Million | GBX5.16 Million | GBX73.21K | ▲ +9.4 pp |
| 2011 | 22.1% | GBX4.69 Million | GBX21.19 Million | GBX4.75 Million | GBX65.63K | ▲ +1.0 pp |
| 2010 | 21.1% | GBX4.50 Million | GBX21.29 Million | GBX4.61 Million | GBX109.60K | ▲ +14.2 pp |
| 2009 | 6.9% | GBX1.14 Million | GBX16.52 Million | GBX1.43 Million | GBX289.43K | ▲ +1.4 pp |
| 2008 | 5.6% | GBX598.85K | GBX10.78 Million | GBX890.98K | GBX292.12K | ▼ -5.6 pp |
| 2007 | 11.1% | GBX727.42K | GBX6.53 Million | GBX902.74K | GBX175.32K | ▼ -21.5 pp |
| 2006 | 32.6% | GBX3.05 Million | GBX9.33 Million | GBX3.06 Million | GBX15.71K | — |